Danish company takes candidate to phase III
MC2 Therapeutics, financed by two wealthy Danish families, has initiated pivotal studies with its first candidate drug, a topical treatment of psoriasis.
BY MIKKEL AABENHUS HEMMINGSEN
The Danish company MC2 Therapeutics has enrolled and treated the first patient in a pivotal phase III trial with the company’s most advanced candidate, the psoriasis cream MC2-01.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
